(2) Polypharmacy and specific drug classes (e.g., acetylcholinesterase inhibitors and HMG-CoA reductase inhibitors) can lead to weight loss, malnutrition, and sarcopenia through alterations in taste, intestinal absorption and metabolism, or elimination of vitamins and minerals, which in turn reflect important components of the fraily phenotype [5, 41]. Here, HMGCR is linked to sarcopenia.